DBV Fundamental Analysis - DBV TECHNOLOGIES SA

Fundamental Rating

Overall DBV gets a fundamental rating of 3 out of 10. We evaluated DBV against 83 industry peers in the Biotechnology industry. DBV has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, DBV is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year DBV has reported negative net income.

DBV had a negative operating cash flow in the past year.

In the past 5 years DBV always reported negative net income.

DBV had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

DBV has a worse Return On Assets (-85.56%) than 73.49% of its industry peers.

Looking at the Return On Equity, with a value of -142.22%, DBV is in line with its industry, outperforming 43.37% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-85.56%
ROE	-142.22%
ROIC	N/A

ROA(3y)-84.27%

ROA(5y)-75.7%

ROE(3y)-172.64%

ROE(5y)-138.93%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 91.34%, DBV belongs to the best of the industry, outperforming 84.34% of the companies in the same industry.

DBV's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for DBV so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	91.34%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, DBV has more shares outstanding

DBV has more shares outstanding than it did 5 years ago.

The debt/assets ratio for DBV is higher compared to a year ago.

2.2 Solvency

DBV has an Altman-Z score of -2.16. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -2.16, DBV is doing worse than 65.06% of the companies in the same industry.

A Debt/Equity ratio of 0.08 indicates that DBV is not too dependend on debt financing.

DBV's Debt to Equity ratio of 0.08 is fine compared to the rest of the industry. DBV outperforms 66.27% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Altman-Z	-2.16

ROIC/WACCN/A

WACC7.84%

2.3 Liquidity

DBV has a Current Ratio of 2.45. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 2.45, DBV perfoms like the industry average, outperforming 53.01% of the companies in the same industry.

DBV has a Quick Ratio of 2.45. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.

DBV has a Quick ratio (2.45) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.45
Quick Ratio	2.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.66% over the past year.

Looking at the last year, DBV shows a very strong growth in Revenue. The Revenue has grown by 224.69%.

Measured over the past years, DBV shows a small growth in Revenue. The Revenue has been growing by 0.50% on average per year.

EPS 1Y (TTM)43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)224.69%

Revenue growth 3Y11.73%

Revenue growth 5Y0.5%

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.26% on average over the next years. This is quite good.

DBV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.93% yearly.

EPS Next Y-36.93%

EPS Next 2Y-1.83%

EPS Next 3Y40.68%

EPS Next 5Y16.26%

Revenue Next Year-55.09%

Revenue Next 2Y271.45%

Revenue Next 3Y438.04%

Revenue Next 5Y75.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DBV. In the last year negative earnings were reported.

Also next year DBV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as DBV's earnings are expected to grow with 40.68% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.83%

EPS Next 3Y40.68%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for DBV!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

DBV TECHNOLOGIES SA

EPA:DBV (1/13/2026, 5:29:51 PM)

2.985

-0.12 (-3.71%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-28 2025-10-28/amc

Earnings (Next)03-23 2026-03-23/amc

Inst Owners69.74%

Inst Owner ChangeN/A

Ins Owners0.1%

Ins Owner ChangeN/A

Market Cap107.31M

Revenue(TTM)15.73M

Net Income(TTM)-122.55M

Analysts80

Price Target5.13 (71.86%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)28.83%

PT rev (3m)29.41%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)22.46%

EPS NY rev (3m)22.97%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)1.37%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	33.02
P/FCF	N/A
P/OCF	N/A
P/B	1.46
P/tB	1.46
EV/EBITDA	N/A

EPS(TTM)-0.65

EYN/A

EPS(NY)-0.67

Fwd EYN/A

FCF(TTM)-2.1

FCFYN/A

OCF(TTM)-2.09

OCFYN/A

SpS0.09

BVpS2.05

TBVpS2.05

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-85.56%
ROE	-142.22%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	91.34%
FCFM	N/A

ROA(3y)-84.27%

ROA(5y)-75.7%

ROE(3y)-172.64%

ROE(5y)-138.93%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.75%

GM growth 5Y-2.02%

F-Score2

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	42.61%
Cap/Sales	8.26%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.45
Quick Ratio	2.45
Altman-Z	-2.16

F-Score2

WACC7.84%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)25.42%

Cap/Sales(5y)23.37%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)43.66%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next Y-36.93%

EPS Next 2Y-1.83%

EPS Next 3Y40.68%

EPS Next 5Y16.26%

Revenue 1Y (TTM)224.69%

Revenue growth 3Y11.73%

Revenue growth 5Y0.5%

Sales Q2Q%N/A

Revenue Next Year-55.09%

Revenue Next 2Y271.45%

Revenue Next 3Y438.04%

Revenue Next 5Y75.93%

EBIT growth 1Y-31.77%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-9.76%

EBIT Next 3Y32.47%

EBIT Next 5YN/A

FCF growth 1Y0.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y0.02%

OCF growth 3YN/A

OCF growth 5YN/A

DBV TECHNOLOGIES SA / DBV.PA FAQ

What is the fundamental rating for DBV stock?

ChartMill assigns a fundamental rating of 3 / 10 to DBV.PA.

What is the valuation status of DBV TECHNOLOGIES SA (DBV.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to DBV TECHNOLOGIES SA (DBV.PA). This can be considered as Overvalued.

Can you provide the profitability details for DBV TECHNOLOGIES SA?

DBV TECHNOLOGIES SA (DBV.PA) has a profitability rating of 1 / 10.

Can you provide the financial health for DBV stock?

The financial health rating of DBV TECHNOLOGIES SA (DBV.PA) is 3 / 10.

DBV TECHNOLOGIES SA (DBV.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

DBV TECHNOLOGIES SA / DBV.PA FAQ

What is the fundamental rating for DBV stock?

What is the valuation status of DBV TECHNOLOGIES SA (DBV.PA) stock?

Can you provide the profitability details for DBV TECHNOLOGIES SA?

Can you provide the financial health for DBV stock?